https://www.biopharmawatch.com/news/ARWR/arrowhead-phase-3-shasta-3-4-plozasiran-results BiopharmaWatch en 2026-08-30T15:30:00.000Z Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia https://www.biopharmawatch.com/news/ALNY/alnylam-esc-congress-2026-data BiopharmaWatch en 2026-08-30T12:23:00.000Z Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings https://www.biopharmawatch.com/news/BMY/bmy-camzyos-long-term-efficacy-esc-congress-2026 BiopharmaWatch en 2026-08-29T15:00:00.000Z Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026 https://www.biopharmawatch.com/news/CYTK/cytokinetics-acacia-hcm-maple-hcm-results-esc-2026 BiopharmaWatch en 2026-08-29T14:30:00.000Z Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026 https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-phase-3-level-results-esc-congress-2026 BiopharmaWatch en 2026-08-29T12:21:00.000Z Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 https://www.biopharmawatch.com/news/TAK/takeda-fda-approval-mimrylo-polycythemia-vera BiopharmaWatch en 2026-08-28T22:40:00.000Z Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera https://www.biopharmawatch.com/news/AIDX/2020-biolabs-investor-webinar-september-2026 BiopharmaWatch en 2026-08-28T22:26:00.000Z 20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity